Allergic Reaction due to Anti-Tuberculosis Drugs, How to Manage?
Downloads
Tuberculosis (TB) still becomes a significant health problem in Indonesia. The first-line anti-tuberculosis drug (ATD) is still the most effective TB drug, but it can have some side effects. One of them is allergic skin reactions that can affect a patient's compliance. Allergic reactions due to ATD are found in 4-6% of TB cases and are the third most frequent side effect after gastrointestinal and liver function disorder. All first-line ATD can cause allergic reactions. Allergic reactions due to ATD can be mild, such as itching and reddish rashes, to severe and life-threatening rashes, such as anaphylactic shock, Steven Johnson Syndrome (SJS), and Toxic Epidermal Necrotic (TEN). The most important things in the management are identifying and stopping drugs. It includes drug challenge and desensitization of causing drug. Desensitization must be distinguished from drug challenge or provocation tests, which are diagnostic tools. The proper management of ATD allergic reactions can improve compliance and patient's outcomes.
Jung HY, Park S, Shin B, et al. Prevalence and Clinical Features of Drug Reactions with Eosinophilia and Systemic Symptoms Syndrome Caused by Antituberculosis Drugs: A Retrospective Cohort Study. Allergy, Asthma Immunol Res 2019; 11: 90–103.
Dedun AR, Borisagar GB, Solanki RN. Impact of Adverse Drug Reaction of First Line Anti-Tuberculous Drugs on Treatment Outcome of Tuberculosis under Revised National Tuberculosis Control Programme. Int J Adv Med 2017; 4: 645.
Marra F, Marra CA, Bruchet N, et al. Adverse Drug Reactions Associated with First-Line Anti-Tuberculosis Drug Regimens. Int J Tuberc Lung Dis 2007; 11: 868–875.
Farazi A, Sofian M, Jabbariasl M, et al. Adverse Reactions to Antituberculosis Drugs in Iranian Tuberculosis Patients. Tuberc Res Treat 2014; 2014: 1–6.
Siripassorn K, Ruxrungtham K, Manosuthi W. Successful Drug Desensitization in Patients with Delayed-Type Allergic Reactions to Anti-Tuberculosis Drugs. Int J Infect Dis 2018; 68: 61–68.
R.J. Lehloenya, G. Todd, M. Badri KD. Outcomes of Reintroducing Anti-Tuberculosis Drugs Following Cutaneous Adverse Drug Reactions. Int J Tuberc Lung Dis 2011; 15: 1649–1655.
Dua R, Sindhwani G, Rawat J. Exfoliative Dermatitis to All Four First Line Oral Anti-Tubercular Drugs. Indian J Tuberc 2010; 57: 53–56.
Medicines Information Center University of Cape Town. Management of Suspected Drug-Induced Rash, Kidney Injury and Liver Injury in Adult Patients on TB Treatment and/or Antiretroviral Treatment. 2018.
Kobashi Y, Abe T, Shigeto E, et al. Desensitization Therapy for Allergic Reactions to Antituberculous Drugs. Intern Med 2010; 49: 2297–2301.
Hamm RL. Drug Allergy: Delayed Cutaneous Hypersensitivity Reactions to Drugs. Cit EMJ Allergy Immunol 2016; 1: 92–101.
Weiss ME, Bernstein DI, Blessing-moore J, et al. Drug Allergy: An Updated Practice Parameter. Ann Allergy, Asthma Immunol 2010; 105: 259-273.e78.
Ministry of Health Singapore. The National Drug Allergy Reporting Guidelines.
Demoly P, Adkinson NF, Bockrow K, et al. International Consensus on Drug Allergy. Allergy Eur J Allergy Clin Immunol 2014; 69: 420–437.
Buhari GK, Keren M, Dursun AB, et al. Immediate-Type Hypersensitivity Reactions due to Antituberculosis Drugs: A Successful Readministration Protocol. Ann Allergy, Asthma Immunol 2015; 115: 39–44.
Abe R. Immunological Response in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. J Dermatol 2015; 42: 42–48.
Unal D, Gelincik A, Elitok A, et al. Impact of High Serum Immunoglobulin E Levels on the Risk of Atherosclerosis in Humans. Asia Pac Allergy 2017; 7: 74.
Ohrui T, Zayasu K, Sato E, et al. Pulmonary Tuberculosis and Serum IgE. Clin Exp Immunol 2000; 122: 13–15.
Ellertsen LK, Storla DG, Diep LM, et al. Allergic Sensitisation in Tuberculosis Patients at the Time of Diagnosis and Following Chemotherapy. BMC Infect Dis 2009; 9: 1–9.
Lehloenya RJ, Dheda K. Cutaneous Adverse Drug Reactions to Anti-Tuberculosis Drugs: State of the Art and into the Future. Expert Rev Anti Infect Ther 2012; 10: 475–486.
Piubello, Alberto, Aí¯t-Khaled, Nadia. Caminero, José A. Chiang, Chen-Yuan. Dlodlo, Riitta A. Fujiwara, Paula I. Heldal E. Field Guide for the Management of Drug-Resistant Field Guide for the Management of Drug-Resistant. 2018.
Harries, a.; Maher, D.; Graham S. TB/HIV a Clinical Manual. 2004. Epub ahead of print 2004. DOI: 10.1016/S0035-9203(97)90302-3.
Kementerian Kesehatan Republik Indonesia. Pedoman Nasional Penanggulangan Tuberkulosis. 2014.
World Health Organization. Treatment of Tuberculosis Guidelines. 2010. Epub ahead of print 2010. DOI: 10.1007/s10405-019-0234-x.
Flick L, Tuberculosis M, Tuberculosis P, et al. Guidelines for the Management of Adverse Drug Effects of Antimycobacterial Agents.
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis an Off Publ Infect Dis Soc Am 2016; 63: e147–e195.
Ait-Khaled N, Enarson DA. Tuberculosis A Manual for Medical Students. Who 2003; 148.
Thong BY-H, Chia FL-A, Tan S-C, et al. A Retrospective Study on Sequential Desensitization-Rechallenge for Antituberculosis Drug Allergy. Asia Pac Allergy 2014; 4: 156.
Cernadas JR, Brockow K, Romano A, et al. General Considerations on Rapid Desensitization for Drug Hypersensitivity - A Consensus Statement. Allergy Eur J Allergy Clin Immunol 2010; 65: 1357–1366.
Collado-Chagoya R, Hernández-Romero J, Eliosa-Alvarado GA, et al. Tolerance Induction to Antituberculosis Drugs in a Patient with Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis Overlap. Allergy Rhinol 2018; 9: 215265671878361.
Thong BY-H. Clinical Applications of Drug Desensitization in the Asia-Pacific Region. Asia Pac Allergy 2011; 1: 2.
Holland CL, Malasky C, Ogunkoya A, et al. Rapid Oral Desensitization to Isoniazid and Rifampin. Chest 1990; 98: 1518–1519.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (